Menu
Search
|

Menu

Close
X

Genomic Health Inc GHDX.OQ (NASDAQ Stock Exchange Global Select Market)

69.37 USD
-5.26 (-7.05%)
As of Mar 22
chart
Previous Close 74.63
Open 74.10
Volume 181,258
3m Avg Volume 155,834
Today’s High 74.37
Today’s Low 69.28
52 Week High 91.03
52 Week Low 30.04
Shares Outstanding (mil) 36.90
Market Capitalization (mil) 2,560.03
Forward P/E 101.41
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
394
FY17
341
FY16
328
EPS (USD)
FY18
0.684
FY17
-0.113
FY16
-0.421
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
101.41
58.10
Price to Sales (TTM)
vs sector
6.50
8.84
Price to Book (MRQ)
vs sector
9.35
4.60
Price to Cash Flow (TTM)
vs sector
65.73
40.07
Total Debt to Equity (MRQ)
vs sector
0.00
17.66
LT Debt to Equity (MRQ)
vs sector
0.00
13.97
Return on Investment (TTM)
vs sector
11.26
12.12
Return on Equity (TTM)
vs sector
11.46
13.24

EXECUTIVE LEADERSHIP

Kimberly Popovits
Chairman of the Board, President, Chief Executive Officer, Since 2012
Salary: $700,128.00
Bonus: $440,360.00
Gordon Cole
Chief Financial Officer, Chief Operating Officer, Since 2016
Salary: $530,400.00
Bonus: $203,870.00
Steven Shak
Chief Scientific Officer, Since 2014
Salary: $499,100.00
Bonus: $191,840.00
Phillip Febbo
Chief Medical Officer, Since 2013
Salary: --
Bonus: --
Laura Kammeyer
Chief Communications Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

301 Penobscot Dr
REDWOOD CITY   CA   94063-4700

Phone: +1650.5569300

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

SPONSORED STORIES